Comparative Pharmacology
Head-to-head clinical analysis: PERGOLIDE MESYLATE versus PRAMIPEXOLE DIHYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERGOLIDE MESYLATE versus PRAMIPEXOLE DIHYDROCHLORIDE.
PERGOLIDE MESYLATE vs PRAMIPEXOLE DIHYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoline-derived dopamine D2 receptor agonist; also activates D1 and D3 receptors, and has antagonist activity at α2-adrenergic and 5-HT2B receptors.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
0.05 mg orally once daily for first 2 days, then increase by 0.1-0.15 mg/day every 3 days over 12 days, then by 0.25 mg/day every 3 days until optimal response; usual therapeutic range 2-3 mg/day divided 3 times daily; maximum 5 mg/day.
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
None Documented
None Documented
Terminal elimination half-life: 15-27 hours (mean 21 hours); clinically relevant for once-daily dosing
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Renal: 50-60% as metabolites; Fecal: 40-50%; Biliary: minor (<5%)
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist